menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Not Confirmed

    envelop Contact Supplier

    CPhI South East Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 1284

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaProviding RSMs & API to Global Pharma CompaniesProviding RSMs & API to Global Pharma Companies

    Providing RSMs & API to Global Pharma Companies
    Providing RSMs & API to Global Pharma Companies

    reelProviding RSMs & API to Global Pharma Companies

    This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

    Impressions: 1771

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    The pharmaceutical industry has witnessed a wave of mergers, acquisitions, and strategic partnerships so far in the first half (H1) of 2025, with deal values exceeding US$ 170 billion.PharmaCompass’ data shows oncology alone accounted for nearly US$ 47 billion in deal value, followed by US$ 18 billion each in immunology and psychiatry, US$ 17 billion in nutrition/weight loss and US$ 7 billion in neurology.Pharma majors such as Johnson & Johnson and Bristol Myers Squibb led with two deals worth over US$ 10 billion each. Sanofi executed a series of deals in the immunology and neuro-inflammation space. And Eli Lilly stood out for its aggressive dealmaking, which spanned oncology, pain, RNA therapies, and AI-driven oligonucleotides. In all, it signed seven deals worth over US$ 1 billion each. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available)H1 records several mega deals as J&J buys Intra-Cellular, BMS ties up with BioNTech, Sanofi acquires BlueprintJohnson & Johnson dominated headlines with its US$ 14.6 billion acquisition of Intra-Cellular Therapies in January 2025. This marks the largest biopharma deal since Novo Nordisk’s US$ 16.5 billion acquisition of Catalent in February 2024. This acquisition positions J&J as a formidable player in the neuroscience space. Bristol Myers Squibb entered into a US$ 11.1 billion partnership with BioNTech. The deal structure — US$ 3.5 billion in unconditional payments and up to US$ 7.6 billion in milestone payments — demonstrates BMS’ confidence in BNT327, a next-generation bispecific antibody in phase 3 trials for treating extensive stage small cell lung cancer and non-small cell lung cancer.Sanofi acquired Blueprint Medicines for US$ 9.5 billion in order to enhance its rare disease portfolio. The French drugmaker is also creating a comprehensive immunology portfolio. The company signed a US$ 1.9 billion deal for Dren Bio’s DR-0201 bispecific antibody for autoimmune diseases. Sanofi also acquired Vigil Neuroscience for US$ 470 million for its phase 2-ready Alzheimer’s disease candidate. Additionally, the drugmaker secured a US$ 1.84 billion global license agreement with Earendil Labs for two next-generation bispecific antibodies.Pfizer’s US$ 6.05 billion partnership with 3SBio provides it global licensing rights (excluding China) for SSGJ-707, a bispecific antibody currently undergoing multiple clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Obesity gold rush sees Roche, AbbVie, Sciwind ink deals; Novo pledges over US$ 5 bn across three dealsThe obesity therapeutics market has triggered intense competition among pharmaceutical giants. Roche’s US$ 5.3 billion partnership with Zealand Pharma is focused on petrelintide, an amylin analog designed to preserve lean mass better than existing GLP-1-based treatments. The collaboration combines petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, creating a differentiated obesity treatment.Market leader Novo Nordisk has promised over US$ 5 billion across three major obesity deals in 2025. The US$ 2.2 billion Septerna collaboration targets oral small molecule medicines for obesity and cardiometabolic diseases.Novo signed a separate US$ 2 billion agreement with China’s United Biotechnology for UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors in phase 2 clinical development for obesity, type 2 diabetes, and other diseases. The company’s third major deal, a US$ 1 billion partnership with Lexicon Pharmaceuticals, provides it access to LX9851, a molecule in preclinical development for obesity and associated metabolic disorders.Sciwind Biosciences secured a US$ 2.5 billion global licensing and collaboration agreement with Verdiva Bio Limited for the global development and commercialization of a portfolio of metabolic diseases therapies. AbbVie entered the amylin arena through its US$ 2.2 billion Gubra partnership for GUB014295, a candidate in phase 1 trials for treating obesity. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Molecular glue degraders draw investments; Lilly signs seven deals over US$ 1 billion eachMolecular glue degraders have emerged as a transformative therapeutic modality, attracting significant investment across multiple partnerships. AbbVie’s US$ 1.64 billion collaboration with Neomorph leverages the biotech’s leading molecular glue discovery platform for oncology and immunology applications.Genentech’s potential US$ 2.1 billion partnership with Orionis Biosciences focuses on small-molecule monovalent glue medicines for novel and challenging oncology targets. This is the second partnership between the two companies, following their initial 2023 collaboration.Eli Lilly has collaborated with Magnet Biomedicine, utilizing Magnet’s TrueGlue discovery platform for oncology applications. The deal could be worth up to US$ 1.3 billion.Eli Lilly has emerged as one of 2025’s most active dealmakers, with approximately seven deals exceeding US$ 1 billion each. The company’s US$ 2.5 billion Scorpion Therapeutics acquisition provides access to STX-478, an experimental oral therapy in early-stage trials for breast cancer and advanced solid tumors, potentially addressing 30 to 40 percent of hormone-positive breast cancer patients.On June 17, Lilly announced the acquisition of gene-editing startup Verve Therapeutics for US$ 1.3 billion. Lilly’s US$ 1 billion SiteOne acquisition announced in May brings STC-004, a phase 2-ready non-opioid chronic pain treatment to its pipeline. Other partnerships announced by Lilly include a US$ 1.4 billion capsid licensing deal with Sangamo for central nervous system disease genomic medicines and a US$ 1.3 billion collaboration with South Korean company Rznomics for RNA-based hearing loss treatments. Lilly has also strengthened its oligonucleotide pipeline through a potential US$ 1 billion collaboration with Creyon Bio for AI-designed oligonucleotide therapies targeting RNA. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Merck KGaA acquires SpringWorks for US$ 3.9 bn; Novartis buys out Anthos for US$ 3.1 bnAstraZeneca signed a US$ 5.3 billion AI-led research agreement with China’s CSPC Pharmaceuticals Group to advance the discovery of novel oral candidates for immunological diseases. Merck KGaA acquired SpringWorks for US$ 3.9 billion in April, which gave it access to two FDA-approved therapies — Ogsiveo (nirogacestat), the first and only approved therapy for adult patients with progressing desmoid tumors requiring systemic treatment, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.Novartis’ US$ 3.1 billion Anthos Therapeutics acquisition centered around abelacimab, a potential first-in-class monoclonal antibody currently in three phase 3 studies for stroke and systemic embolism prevention in atrial fibrillation patients.GSK’s US$ 2 billion acquisition of Boston Pharmaceuticals’ efimosfermin targets steatotic liver disease (fatty liver disease). The medicine is also in clinical development for MASH treatment. GSK’s second major deal involved the US$ 1.15 billion acquisition of US biotech IDRx, strengthening its gastrointestinal cancer portfolio.The pharma industry also drew some private equity interest as Bain Capital acquired Japan’s Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group for US$ 3.3 billion. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Our viewDespite an uncertain geopolitical environment, the year has seen a surge in M&As and dealmaking in the first half of 2025. However, a sizable chunk of the acquisitions were bolt-on transactions, indicating that companies are not ready to take on risks, and are buying out smaller players who strategically fit into their operations. Going forward, there are indications that M&A activity will stay strong throughout 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6678

    https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

    #PharmaFlow by PHARMACOMPASS
    19 Jun 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis gets Approval for First malaria drug for babies
    Novartis gets Approval for First malaria drug for babies

    08 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-gets-approval-first-malaria-drug-babies-children-2025-07-08/

    REUTERS
    08 Jul 2025
    Share Share
    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease
    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease

    05 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-cosentyx-fails-late-stage-trial-artery-disease-2025-07-03/

    REUTERS
    05 Jul 2025
    Share Share
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets

    27 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-pens-profound-pact-offering-750m-biobucks-cardiovascular-target

    FIERCE BIOTECH
    27 Jun 2025
    Share Share
    Novartis completes acquisition of Regulus Therapeutics
    Novartis completes acquisition of Regulus Therapeutics

    25 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/25/3105176/0/en/Novartis-completes-acquisition-of-Regulus-Therapeutics.html

    GLOBENEWSWIRE
    25 Jun 2025
    Share Share
    Amneal, Kashiv Report Positive Data for Xolair Biosimilar
    Amneal, Kashiv Report Positive Data for Xolair Biosimilar

    25 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/25/3105002/0/en/Amneal-Highlights-Positive-Topline-Results-from-Confirmatory-Clinical-Study-of-Biosimilar-Candidate-to-XOLAIR-R-omalizumab-Developed-by-Kashiv-BioSciences.html

    GLOBENEWSWIRE
    25 Jun 2025
    Share Share
    Novartis HSR waiting period for Regulus Therapeutics offer ends
    Novartis HSR waiting period for Regulus Therapeutics offer ends

    23 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/23/3103089/0/en/Novartis-announces-expiration-of-HSR-waiting-period-of-Regulus-Therapeutics-tender-offer.html

    GLOBENEWSWIRE
    23 Jun 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Pentetreotide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Pentetreotide

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 9906

    Submission : 1992-10-09

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 227MF10097

    Registrant's Address : Lichtstrasse 35, CH-4056 Basel, Switzerland

    Initial Date of Registration : 2015-04-09

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Valsartan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Valsartan

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23902

    Submission : 2010-07-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2016-290 - Rev 03

    Issue Date : 2024-10-16

    Type : Chemical

    Substance Number : 2423

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea Ltd.

    Registration Date : 2011-12-09

    Registration Number : 20111209-135-H-172-28

    Manufacturer Name : Novartis Grimsby Ltd.

    Manufacturer Address : Moody Lane, Pyewipe, Grimsby_N.E. Lincolnshire/DN31 2SR/England

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Amlodipine Besylate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Amlodipine Besylate

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2008-122 - Rev 02

    Issue Date : 2023-12-14

    Type : Chemical

    Substance Number : 1491

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 0078-1476

    Start Marketing Date : 2007-06-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Baclofen

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Baclofen

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 9643

    Submission : 1992-04-15

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Fluvastatin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Fluvastatin

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23901

    Submission : 2010-06-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Glycolide - lactide copolymer

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Glycolide - lactide copolymer

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 6895

    Submission : 1987-03-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Letrozole

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Letrozole

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2019-149 - Rev 00

    Issue Date : 2020-09-03

    Type : Chemical

    Substance Number : 2334

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea Ltd.

    Registration Date : 2021-07-27

    Registration Number : 20210727-209-J-1080

    Manufacturer Name : Novartis Pharma Schweizerhalle AG@Novartis Pharma Stein AG

    Manufacturer Address : Rothausstrasse, 4133, Pratteln, Switzerland@Schaffhauserstrasse, 4332 Stein, Switzerland

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Lutetium Chloride Lu-177

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Lutetium Chloride Lu-177

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31705

    Submission : 2017-05-02

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    NAFTIFINE HCL

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    NAFTIFINE HCL

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 16772

    Submission : 2003-08-19

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Terbinafine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    EPS
    Not Confirmed
    arrow

    Terbinafine

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    EPS
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27059

    Submission : 2013-06-07

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : G-Therapeutics Korea Co., Ltd.

    Registration Date : 2011-02-15

    Registration Number : 20110215-49-A-244-16

    Manufacturer Name : Novartis Ringaskiddy Limited

    Manufacturer Address : Ringaskiddy, Co. Cork

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Cadent Therapeutics and get a quotation

    Cadent Therapeutics is a supplier offers 70 products (APIs, Excipients or Intermediates).

    Find a price of Pentetreotide bulk with DMF, JDMF offered by Cadent Therapeutics

    Find a price of Valsartan bulk with DMF, CEP offered by Cadent Therapeutics

    Find a price of Amlodipine Besylate bulk with CEP offered by Cadent Therapeutics

    Find a price of Baclofen bulk with DMF offered by Cadent Therapeutics

    Find a price of Cefepime Hydrochloride bulk with JDMF offered by Cadent Therapeutics

    Find a price of Ceftriaxone bulk with JDMF offered by Cadent Therapeutics

    Find a price of Cyclosporine bulk with JDMF offered by Cadent Therapeutics

    Find a price of Fluvastatin bulk with DMF offered by Cadent Therapeutics

    Find a price of Glycolide - lactide copolymer bulk with DMF offered by Cadent Therapeutics

    Find a price of Letrozole bulk with CEP offered by Cadent Therapeutics

    Find a price of NAFTIFINE HCL bulk with DMF offered by Cadent Therapeutics

    Find a price of Penicillin G Benzathine bulk with JDMF offered by Cadent Therapeutics

    Find a price of Terbinafine bulk with DMF offered by Cadent Therapeutics

    Find a price of Topotecan Hydrochloride bulk with DMF offered by Cadent Therapeutics

    Find a price of Benzonatate bulk offered by Cadent Therapeutics

    Find a price of Bisoctrizole bulk offered by Cadent Therapeutics

    Find a price of Chlorthalidone bulk offered by Cadent Therapeutics

    Find a price of Clofazimine bulk offered by Cadent Therapeutics

    Find a price of Clomipramine Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Edotreotide bulk offered by Cadent Therapeutics

    Find a price of Eudragit Rs bulk offered by Cadent Therapeutics

    Find a price of Methylphenidate Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Naphazoline Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Pyrilamine bulk offered by Cadent Therapeutics

    Find a price of Pyrilamine Maleate bulk offered by Cadent Therapeutics

    Find a price of Rifampicin bulk offered by Cadent Therapeutics

    Find a price of Thurfyl Nicotinate bulk offered by Cadent Therapeutics

    Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Cadent Therapeutics

    Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Cadent Therapeutics

    Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Cadent Therapeutics

    Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Cadent Therapeutics

    Find a price of TINUVIN 326 bulk offered by Cadent Therapeutics

    Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Cadent Therapeutics

    Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Cadent Therapeutics

    Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Cadent Therapeutics

    Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Cadent Therapeutics

    Find a price of TESSALON DRUG SUBSTANCE bulk offered by Cadent Therapeutics

    Find a price of CGP 17,582B bulk offered by Cadent Therapeutics

    Find a price of Alpelisib bulk offered by Cadent Therapeutics

    Find a price of Asciminib bulk offered by Cadent Therapeutics

    Find a price of Atorvastatin bulk offered by Cadent Therapeutics

    Find a price of Dabrafenib Mesylate bulk offered by Cadent Therapeutics

    Find a price of Deferasirox bulk offered by Cadent Therapeutics

    Find a price of Diclofenac Diethylamine bulk offered by Cadent Therapeutics

    Find a price of Everolimus bulk offered by Cadent Therapeutics

    Find a price of Fingolimod Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Fluvastatin Sodium bulk offered by Cadent Therapeutics

    Find a price of Hydrochlorothiazide bulk offered by Cadent Therapeutics

    Find a price of Indacaterol Maleate bulk offered by Cadent Therapeutics

    Find a price of Iptacopan Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Ketotifen Fumarate bulk offered by Cadent Therapeutics

    Find a price of Lithium Carbonate bulk offered by Cadent Therapeutics

    Find a price of Mycophenolate Mofetil bulk offered by Cadent Therapeutics

    Find a price of Mycophenolate Sodium bulk offered by Cadent Therapeutics

    Find a price of Nilotinib bulk offered by Cadent Therapeutics

    Find a price of Osilodrostat Phosphate bulk offered by Cadent Therapeutics

    Find a price of Oxcarbazepine bulk offered by Cadent Therapeutics

    Find a price of Pimecrolimus bulk offered by Cadent Therapeutics

    Find a price of Ribociclib bulk offered by Cadent Therapeutics

    Find a price of Rivastigmine bulk offered by Cadent Therapeutics

    Find a price of Rivastigmine Tartrate bulk offered by Cadent Therapeutics

    Find a price of Tacrolimus bulk offered by Cadent Therapeutics

    Find a price of Terbinafine Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Trametinib bulk offered by Cadent Therapeutics

    Find a price of Valsartan bulk offered by Cadent Therapeutics

    Find a price of Vildagliptin bulk offered by Cadent Therapeutics

    Find a price of Ashmini hydrochloride bulk offered by Cadent Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search